Clinical Trials Logo

Filter by:
NCT ID: NCT06468098 Recruiting - Clinical trials for Advanced Malignancies

A Study of IBI363 in Subjects With Advanced Malignancies

Start date: May 31, 2024
Phase: Phase 1
Study type: Interventional

This is an open-label, multicenter Phase Ib study to evaluate the safety, tolerability, and efficacy of IBI363 in advanced malignancies patients

NCT ID: NCT06467942 Recruiting - Clinical trials for Human Papilloma Virus Infection

Effects of Chinese Medicine and Lactobacillus in Persistent HPV Infection

ELIMVLHPV
Start date: March 1, 2023
Phase: N/A
Study type: Interventional

High risk human papillomavirus (hr-HPV) persistent infection is a high risk factor for cervical cancer. 85% to 90% of hr-HPV infections have the ability to clear on their own, while 10% to 15% of HPV persists further will lead to the development of high-grade intraepithelial lesions (HSIL) and even to invasive cervical cancer. Long-term follow-up results for persistent hr-HPV infection showed that cervical HSIL mostly occurred after 5-7 years of persistent hr-HPV infection, among which the risk of HPV16 and 18 was the highest, followed by HPV31 and 33. The role of the vaginal microbiome (CVM) in persistent hr-HPV infection has been increasingly valued, and women with persistent HPV infection that progresses to HSIL have a more unstable vaginal microenvironment. The previous study found that Lactobacillus vaginalis may contribute to HPV clearance by improving the vaginal microenvironment. In addition, previous studies have found that estrogen-like Chinese medicine could increase glycogen, improve mucosal estrogen levels, increase lactobacillus content, and promote HPV clearance. It is a challenge to make clinical management on when and how to intervene among hr-HPV persistent infection but whose pathology does not suggest HSIL. This study intends to analyze the correlation between the duration of HPV infection and the current vaginal microbiome, HPV load and PAX1 methylation in people with persistent HPV infection at different ages, and observe the changes of the above indicators after the administration of drugs to improve the vaginal microenvironment, which is helpful for preventing HPV persistent infection and developing into true precancerous lesions. It has the clinical and practical value of "preparing for a rainy day".

NCT ID: NCT06467864 Recruiting - Clinical trials for Respiratory Tract Infections

Predicting Ventilator-associated Lower Respiratory Tract Infection Outcomes Using Sequenced-based Early Microbiological Response: A Multi-center Prospective Study

Start date: July 1, 2024
Phase:
Study type: Observational [Patient Registry]

We are using a tool called QtNGS to measure the abundance of local pathogens in patients with ventilator-associated lower respiratory tract infections. We hypothesize that changes in pathogen abundance before and after treatment are related to patient outcomes. This study aims to evaluate the effectiveness of the tool by analyzing the changes in pathogen abundance and exploring the relationship between these changes and clinical outcomes.

NCT ID: NCT06467851 Completed - Chronic Insomnia Clinical Trials

Effect of Suanzaoren Decoction and Huanglian Wendan Decoction on Biorhythm of Insomnia Patients

Start date: August 31, 2023
Phase: N/A
Study type: Interventional

The purpose of this study was to examine the impact of Chinese medicine on melatonin levels in patients with insomnia

NCT ID: NCT06467786 Recruiting - Clinical trials for Small Cell Lung Cancer

Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer

Start date: March 15, 2024
Phase: Phase 4
Study type: Interventional

This study is a prospective, multicenter, single arm Phase II exploratory study. It is expected to include 24 first-line patients with small cell lung cancer who have progressed after 6 months of treatment with platinum containing regimens, and receive treatment with irinotecan liposomes combined with cisplatin or carboplatin regimens.

NCT ID: NCT06467773 Not yet recruiting - Clinical trials for Central Nervous System Diseases

TSPO-PET/MRI in Surveillance of Neuroinflammation in the Central Nervous System

Start date: June 2024
Phase:
Study type: Observational

Central Nervous System (CNS) inflammation is an immune response activated in the brain and spinal cord by microglial cells and astrocytes, commonly occurring under conditions such as CNS ischemia, autoimmunity, infection, toxins, and trauma. Microglial cells, as the innate immune cells of the CNS, are responsible for driving the inflammatory response and play a crucial role in sensing environmental changes, responding to harmful stimuli, and engulfing dead neurons. They also present antigens to T lymphocytes, mediating interactions between the peripheral immune system and the CNS. Factors released by neuronal cells can either promote or inhibit inflammation, and monitoring the level of inflammation driven by microglial cells is essential for the diagnosis and treatment of CNS diseases. MRI is the primary imaging method for CNS inflammation, but it can be challenging to diagnose. PET/MR, a technology that integrates PET and MR imaging, provides high-quality diagnostic images and is valuable for the early detection, diagnosis, and assessment of CNS diseases. The radioactive ligand 18F-DPA-714 PET, targeting the translocation protein (TSPO), can visualize activated microglial cells, which may have a gain effect in detecting active CNS inflammation. This study aims to explore the application of 18F-DPA-714 PET/MR in the early diagnosis, treatment evaluation, and prognosis of CNS inflammation.

NCT ID: NCT06467617 Not yet recruiting - Clinical trials for Non Small Cell Lung Cancer

Adebrelimab Plus Chemo and Recaticimab Perioperative Treatment for Resectable NSCLC

Start date: July 1, 2024
Phase: Phase 2
Study type: Interventional

Current studies confirmed that the immune peri-operative treatment with combination chemotherapy curative effect and safety of resectable NSCLC, but its short-term curative effect and long-term survival benefit remains to be further improved to explore the new way of immune combination therapy. Experimental study showed that the inhibition of PCSK9 could significantly increase in tumor cells of the immune response in mice, inhibit the PCSK9 enhanced anti-tumor immune response of mice can be further coordinate with immune checkpoint therapy, forming a lasting anti-tumor immune effect. There are no reports on the peri-operative treatment of immune combined with chemotherapy and PCSK-9 inhibitors in patients with resectable NSCLC. Based on the above, the aim of this study is to explore the efficacy and safety of Adebrelimab combined with recaticimab and chemotherapy in the peri-operative treatment of patients with resectable NSCLC.

NCT ID: NCT06467591 Completed - Stomach Neoplasms Clinical Trials

Prediction Model for Advanced Gastric Cancer in Elderly

Start date: January 1, 2024
Phase:
Study type: Observational

This study aims to develop and validate a Nomogram (mCNS) model for predicting long-term survival in elderly patients following curative resection for advanced gastric cancer. The study is a retrospective multi-center analysis involving 924 gastric cancer patients treated at the Department of Gastrointestinal Surgery of the Affiliated Union Hospital of Fujian Medical University between 2009 and 2013, and 512 patients aged 65 and above who underwent gastric resection at the Affiliated Zhongshan Hospital of Dalian University between 2011 and 2018. An online prognostic tool is introduced to assist clinicians in predicting patient prognosis and customizing treatment and follow-up strategies.

NCT ID: NCT06467565 Recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

NALIRIFOX as Induction Therapy in LAPC

Start date: December 25, 2023
Phase: Phase 2
Study type: Interventional

This is a prospective, single arm, single center, phase II study of NALIRIFOX as conversion therapy in patients with locally advanced pancreatic cancer.

NCT ID: NCT06467513 Recruiting - Heart Diseases Clinical Trials

To Investigate the Effect of Esketamine Hydrochloride on Pulmonary Complications

Start date: January 1, 2024
Phase: Phase 4
Study type: Interventional

The objective of this study was to evaluate the effect of esketamine on intraoperative hemodynamics in patients with heart valve replacement and to mitigate postoperative pulmonary complications